Safety, Tolerability, and Immunogenicity of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Healthy Infants
Key facts
- Who runs it
- Vaxcyte, Inc.
- Where
- Bardstown, Burleson, Charlottesville, Cranberry Township, Dayton, Erie, Hastings, Haughton, Houston, Jefferson Hills, Jonesboro, Kingsport, Layton, Lincoln, Madera, Murray, North Charleston, Pittsburgh, Provo, Richmond, Roy, Simpsonville, Summerville, Syracuse, and Tampa, United StatesSee the 29 sites
- Trial code
- Status
- Completed
- Phase
- Phase 2
- People taking part
- 802 people enrolled
- Started
- 29 Mar 2023
- Ended
- 25 Aug 2025
- Type of study
- Interventional, 4 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- 0.5 ml dose of 1.1 mcg VAX-24
- 0.5 ml dose of PCV20
- 0.5 ml dose of 2.2 mcg VAX-24
- 0.5 ml dose of 2.2/4.4 mcg VAX-24
- Record updated
- 11 September 2025
Who can take part
- Age
- 42 days to 89 days
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 21 criteriaShow less
Who can take part
- Healthy male or female infant ≥42 days to ≤89 days (inclusive)
- Full-term infant at least 37 weeks gestational age at birth
- Afebrile for ≥72 hours with a rectal temperature <38.0°C (<100.4°F) or axillary temperature <37.8°C (<100.0°F) before receipt of study vaccine.*
- Able to attend all scheduled visits and comply with the study procedures
- Subject's parent/legal guardian is able to read and understands the study procedures, alternate treatments, risks and benefits, and provides written informed consent
- Subject's parent/legal guardian is able to fill out an ediary of solicited AE and take daily axillary temperature and measurements of local injection site reactions for the 7 days after each study vaccination
- Subject's parent/legal guardian has an e-mail address and access to a computer or smartphone with internet to complete the ediary
Who cannot take part
- Previous receipt of a licensed or investigational vaccine (excluding 1 dose hepatitis B vaccine)
- Use of any immunosuppressive therapy (Note: topical and inhaled/nebulized steroids are permitted)
- Receipt of any investigational study product since birth, currently participating in another interventional investigational study, or having plans to receive another investigational product(s) while on study
- History of invasive pneumococcal disease (positive blood culture, positive cerebrospinal fluid culture, or other sterile site) or known history of other culture positive pneumococcal disease
- Known hypersensitivity to any vaccine
- Known or suspected impairment of immunological function (e.g., asplenia, HIV, primary immunodeficiency)
- History of failure to thrive
- Subject has a coagulation disorder contraindicating IM vaccination
- Subject or his/her mother have documented hepatitis B surface antigen-positive
- Has a known neurologic or cognitive behavioral disorder
- Has a known clinically significant congenital malformation or serious chronic disorder
- Receipt of a blood transfusion or blood products, including immunoglobulins
- Any infant who cannot be adequately followed for safety according to the protocol plan
- Any other reason that in the opinion of the investigator may interfere with the evaluation required by the study
Where in United States
- Kentucky Pediatric/ Adult ResearchBardstown, United States
- Ventavia Research GroupBurleson, United States
- Pediatric Research of Charlottesville, LLCCharlottesville, United States
- UPMC Bass Wolfson CranberryCranberry Township, United States
- Ohio Pediatric Research Assn.Dayton, United States
- Allegheny Health and Wellness PavilionErie, United States
- Meridian Clinical ResearchHastings, United States
- ACC Pediatric ResearchHaughton, United States
- Kool Kids PediatricsHouston, United States
- Pediatric AssociatesHouston, United States
- VentaviaHouston, United States
- UPMC Children's Community Pediatrics South Hills-Jefferson HillsJefferson Hills, United States
- The Children's Clinic of Jonesboro, P.AJonesboro, United States
- Holston Medical Group.Kingsport, United States
- Alliance for Multispecialty ResearchLayton, United States
- Midwest Children's Health Research InstituteLincoln, United States
- Madera Family Medical GroupMadera, United States
- Alliance for Multispecialty ResearchMurray, United States
- Palmetto Pediatrics, PANorth Charleston, United States
- UPMC Children's Community Pediatrics Bass Wolfson-Squirrel HillPittsburgh, United States
- UPMC Children's Community Pediatrics-Castle ShannonPittsburgh, United States
- UPMC Primary Care Center OaklandPittsburgh, United States
- Alliance for Multispecialty ResearchProvo, United States
- Pediatric CenterRichmond, United States
- Alliance for Multispecialty ResearchRoy, United States
- Tribe Clinical Research at Parkside PediatricsSimpsonville, United States
- Coastal Pediatric ResearchSummerville, United States
- Alliance for Multispecialty ResearchSyracuse, United States
- Jedidiah Clinical ResearchTampa, United States
About the trial
What the trial wants to find out
The objective of the study is to evaluate the safety and tolerability of 4 injections of VAX-24 (at 3 dose levels) compared to PCV15 in infants at 2, 4, 6, and 12-15 months of age, in addition to receiving routine US concomitant vaccines. Stage 1 of the study will comprise 3 dose ascending cohorts. Stage 2 of the study will enroll the remainder of the sample size.
The 4 groups in the trial
- VAX-24 LowTreatment being tested
Participants will receive 4 doses of VAX-24 administered as an intramuscular injection at 2, 4, 6, and 12-15 months of age at one of three dose levels.
Treatment: 0.5 ml dose of 1.1 mcg VAX-24
- VAX-24 MidTreatment being tested
Participants will receive 4 doses of VAX-24 administered as an intramuscular injection at 2, 4, 6, and 12-15 months of age at one of three dose levels.
Treatment: 0.5 ml dose of 2.2 mcg VAX-24
- VAX-24 MixedTreatment being tested
Participants will receive 4 doses of VAX-24 administered as an intramuscular injection at 2, 4, 6, and 12-15 months of age at one of three dose levels.
Treatment: 0.5 ml dose of 2.2/4.4 mcg VAX-24
- PCV20Existing treatment, for comparison
Participants will receive 4 doses of PCV20 administered as an intramuscular injection of the standard dose at 2, 4, 6, and 12-15 months of age.
Treatment: 0.5 ml dose of PCV20
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Randomized, Observer-Blind, Active-Controlled, Dose-Finding Study to Evaluate the Safety, Tolerability, and Immunogenicity of 24-Valent PCV (VAX-24) in Infants Given 4 Doses at 2, 4, 6, and 12-15 Months of Age With Pediatric Vaccines
- Record updated
- 11 September 2025